Volitionrx Stock Price, News & Analysis

VolitionRx Limited (NYSE AMERICAN: VNRX) is set to host a Capital Markets Day on May 11, 2023, at 2 p.m. Eastern Time, in a hybrid format at the New York Stock Exchange and via live webcast. The event will feature presentations by the executive team and recognized experts in the field, including Dr. Andy Retter and veterinary oncologists Professor Heather Wilson-Robles and Dr. Sue Ettinger. Topics will include the company's corporate strategy, Nu.Q® technology applications in sepsis, and veterinary diagnostics. A Q&A session will follow the presentations. Interested attendees can register for the event virtually or contact for in-person attendance. The event will also be webcasted, with presentations available on Volition's website post-event. VolitionRx focuses on cost-effective blood tests for diagnosing and monitoring diseases like cancer.

VolitionRx Limited (NYSE AMERICAN: VNRX) reported its full fiscal year 2022 results, highlighting a 240% revenue increase to approximately $300,000. The company secured global licensing agreements with Heska Corporation and IDEXX Laboratories for its Nu.Q® Vet Cancer Test, generating an upfront payment of $10 million and potential milestone payments up to $18 million. Cash and equivalents stood at $10.9 million as of December 31, 2022, after raising $8 million through a public offering. Volition continues to expand its intellectual property portfolio, holding 34 patent families and 97 granted patents. A conference call is scheduled for March 16, 2023, to discuss the results.

VolitionRx Limited (AMEX: VNRX) has announced a conference call scheduled for March 16, 2023, at 08:30 a.m. Eastern Time, to discuss its full fiscal year 2022 financial and operating results, along with a business update. CEO Cameron Reynolds, along with other executives, will address key events from 2022 and future milestones. A live audio webcast will be available on Volition's investor relations page, and a replay will be accessible until March 30, 2023. VolitionRx specializes in developing cost-effective blood tests for diagnosing and monitoring diseases using its proprietary Nu.Q® platform.

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the completion of its underwritten public offering of 4,945,000 shares at $1.75 per share, yielding approximately $8.7 million in gross proceeds. The offering included full exercise of the underwriter's overallotment option. Net proceeds will be allocated for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions. The shares were issued under a previously filed shelf registration statement with the SEC. Newbridge Securities Corporation acted as the sole book-running manager for this offering.